Incyte Corporation (INCY)
Largest Insider Buys in Sector
INCY Stock Price History Chart
INCY Stock Performance
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Insider Activity of Incyte Corporation
Over the last 12 months, insiders at Incyte Corporation have bought $0 and sold $3.73M worth of Incyte Corporation stock.
On average, over the past 5 years, insiders at Incyte Corporation have bought $86.42M and sold $22.42M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 84 shares for transaction amount of $6,044 was made by BAKER FELIX () on 2022‑03‑08.
List of Insider Buy and Sell Transactions, Incyte Corporation
| 2024-06-12 | Sale | Flannelly Barry P | EVP & General Manager US | 19,164 0.0086% | $60.00 | $1.15M | +4.59% | |
| 2024-06-06 | Sale | Tray Thomas | Principal Accounting Officer | 1,093 0.0005% | $58.91 | $64,389 | +6.55% | |
| 2024-01-03 | Sale | Stein Steven H | EVP & Chief Medical Officer | 7,365 0.0033% | $65.51 | $482,481 | -11.36% | |
| 2024-01-02 | Sale | Iyengar Vijay K | EVP, GMAPPS | 657 0.0003% | $65.00 | $42,705 | -10.73% | |
| 2023-12-13 | Sale | Tray Thomas | Principal Accounting Officer | 1,067 0.0005% | $62.37 | $66,549 | -8.93% | |
| 2023-12-12 | Sale | Tray Thomas | Principal Accounting Officer | 210 <0.0001% | $57.36 | $12,046 | -5.45% | |
| 2023-09-01 | Sale | SWAIN PAULA J | EVP, Human Resources | 8,449 0.0038% | $65.13 | $550,283 | -10.51% | |
| 2023-08-01 | Sale | Stein Steven H | EVP & Chief Medical Officer | 21,511 0.0096% | $63.28 | $1.36M | -8.32% | |
| 2023-01-31 | Sale | Pasquale Maria E | EVP & General Counsel | 802 0.0004% | $84.06 | $67,416 | -25.80% | |
| 2023-01-30 | Sale | Pasquale Maria E | EVP & General Counsel | 35,212 0.016% | $84.76 | $2.98M | -24.44% | |
| 2023-01-26 | Sale | Dhanak Dashyant | EVP & Chief Scientific Officer | 2,419 0.0011% | $85.00 | $205,615 | -26.33% | |
| 2023-01-26 | Sale | Iyengar Vijay K | EVP, GMAPPS | 7,000 0.0031% | $85.00 | $595,000 | -26.33% | |
| 2023-01-04 | Sale | Stein Steven H | EVP & Chief Medical Officer | 28,399 0.0129% | $79.78 | $2.27M | -19.21% | |
| 2022-12-23 | Sale | Iyengar Vijay K | EVP, GMAPPS | 9,458 0.0042% | $80.80 | $764,166 | -21.29% | |
| 2022-12-19 | Sale | Tray Thomas | Principal Accounting Officer | 1,223 0.0006% | $82.16 | $100,482 | -20.31% | |
| 2022-07-22 | Sale | Tray Thomas | Principal Accounting Officer | 1,564 0.0007% | $83.13 | $130,015 | -9.00% | |
| 2022-07-07 | Sale | Flannelly Barry P | EVP & General Manager US | 2,873 0.0013% | $79.38 | $228,059 | -8.57% | |
| 2022-07-07 | Sale | Iyengar Vijay K | EVP, GMAPPS | 5,787 0.0026% | $79.38 | $459,372 | -8.57% | |
| 2022-04-08 | Sale | Flannelly Barry P | EVP & General Manager US | 881 0.0004% | $82.96 | $73,088 | -8.61% | |
| 2022-03-08 | BAKER FELIX | 84 <0.0001% | $71.95 | $6,044 | +8.15% |
Insider Historical Profitability
| Stein Steven H | EVP & Chief Medical Officer | 90218 0.0403% | $61.75 | 0 | 13 | |
| SWAIN PAULA J | EVP, Human Resources | 77530 0.0346% | $61.75 | 1 | 39 | +27.11% |
| Flannelly Barry P | EVP & General Manager US | 66377 0.0324% | $61.75 | 0 | 19 | |
| Iyengar Vijay K | EVP, GMAPPS | 43412 0.0194% | $61.75 | 0 | 14 | |
| Tray Thomas | Principal Accounting Officer | 21634 0.0105% | $61.75 | 0 | 5 | |
| BAKER BROS. ADVISORS LP | 33039604 14.7426% | $61.75 | 11 | 0 | +3.8% | |
| BAKER JULIAN | director | 19757285 8.8159% | $61.75 | 8 | 0 | +17.75% |
| Baker Brothers Life Sciences Capital (GP), LLC | director, 10 percent owner | 12430783 5.5468% | $61.75 | 51 | 5 | +21.96% |
| Baker Biotech Capital (GP), LLC | director, 10 percent owner | 2933021 1.3087% | $61.75 | 43 | 5 | +21.05% |
| BAKER FELIX | 2926657 1.3059% | $61.75 | 1 | 0 | +8.15% | |
| TISCH THOMAS J | other | 1416661 0.6321% | $61.75 | 1 | 0 | +52.29% |
| TISCH JAMES S | other | 1216661 0.5429% | $61.75 | 1 | 0 | +52.29% |
| TISCH ANDREW H | other | 1216661 0.5429% | $61.75 | 1 | 0 | +52.29% |
| TISCH DANIEL R | other | 1216661 0.5429% | $61.75 | 1 | 0 | +52.29% |
| BAKER BIOTECH CAPITAL II GP LLC | 10 percent owner | 1091407 0.487% | $61.75 | 2 | 0 | +39.59% |
| WHITFIELD ROY A | director | 621082 0.2771% | $61.75 | 0 | 22 | |
| 14159 capital (GP), LLC | director, 10 percent owner | 355839 0.1588% | $61.75 | 50 | 5 | +21.76% |
| Hoppenot Herve | Chairman / CEO | 284231 0.1268% | $61.75 | 2 | 3 | +4.34% |
| FRIEDMAN PAUL A | director | 255531 0.114% | $61.75 | 12 | 20 | +76.59% |
| Baker Bros. Capital (GP), LLC | director, 10 percent owner | 239258 0.1068% | $61.75 | 42 | 5 | +21.44% |
| BROOKE PAUL A | director | 196756 0.0878% | $61.75 | 3 | 2 | +3.81% |
| Baker / Tisch Capital (GP), LLC | director, 10 percent owner | 159739 0.0713% | $61.75 | 29 | 5 | +15.27% |
| Wenqing Yao | EVP, Head of Discovery Chem | 94080 0.042% | $61.75 | 0 | 18 | |
| DE SCHUTTER RICHARD U | director | 92290 0.0412% | $61.75 | 2 | 6 | +19.54% |
| Pasquale Maria E | EVP & General Counsel | 68524 0.0306% | $61.75 | 0 | 11 | |
| METCALF BRIAN W | Chief Drug Discovery Scientist | 66504 0.0297% | $61.75 | 2 | 4 | +24.57% |
| Dhanak Dashyant | EVP & Chief Scientific Officer | 53263 0.0238% | $61.75 | 0 | 19 | |
| ARIKO BARRY A | director | 45834 0.0205% | $61.75 | 0 | 3 | |
| Morrissey Michael James | EVP, Head of Tech. Operations | 45452 0.0203% | $61.75 | 0 | 1 | |
| Friedman Steven M. | EVP, Biology & Preclinical Dev | 38137 0.017% | $61.75 | 0 | 1 | |
| Huber Reid M | EVP, Chief Scientific Officer | 35183 0.0157% | $61.75 | 0 | 10 | |
| Trower Paul | Principal Accounting Officer | 32268 0.0144% | $61.75 | 0 | 14 | |
| Dickinson Jonathan Elliott | EVP, General Manager, Europe | 30214 0.0135% | $61.75 | 0 | 2 | |
| Siegel Eric H. | EVP, General Counsel | 21733 0.0097% | $61.75 | 0 | 26 | |
| DIXON WENDY L | director | 17259 0.0077% | $61.75 | 1 | 5 | +44.82% |
| Levy Richard S | EVP, Chief Drug Dev Officer | 16926 0.0076% | $61.75 | 0 | 34 | |
| GRYSKA DAVID W | Executive Vice President, CFO | 10970 0.0049% | $61.75 | 0 | 7 | |
| BIENAIME JEAN JACQUES | director | 8646 0.0039% | $61.75 | 6 | 3 | <0.0001% |
| HASTINGS DAVID C | Chief Financial Officer | 8500 0.0038% | $61.75 | 3 | 8 | +39.74% |
| SCHRECK PATRICIA A | EVP, General Counsel | 4500 0.002% | $61.75 | 2 | 4 | +35.88% |
| Daly James M | EVP, Chief Commercial Officer | 3521 0.0016% | $61.75 | 0 | 16 | |
| Chardonnet Laurent | 2905 0.0013% | $61.75 | 1 | 13 | +38.15% |
Institutional Investor Ownership
| Baker Bros Advisors LP | $2.06B | 16.11 | 36.18M | +<0.01% | +$30,934.71 | 25.89 | |
| BlackRock | $1.32B | 10.35 | 23.24M | -4.35% | -$60.25M | 0.03 | |
| The Vanguard Group | $1.29B | 10.12 | 22.72M | +0.87% | +$11.19M | 0.03 | |
| Dodge & Cox | $878.25M | 6.87 | 15.42M | -4.19% | -$38.42M | 0.51 | |
| State Street | $563.98M | 4.41 | 9.9M | -2.18% | -$12.57M | 0.02 | |
| Renaissance Technologies | $323.39M | 2.53 | 5.68M | +2.21% | +$6.98M | 0.51 | |
| Geode Capital Management | $252.33M | 1.98 | 4.44M | +3.9% | +$9.46M | 0.02 | |
| Morgan Stanley | $166.48M | 1.3 | 2.92M | -12.91% | -$24.69M | 0.01 | |
| Amundi | $149.03M | 1.26 | 2.82M | -7.57% | -$12.2M | 0.06 | |
| Invesco | $160.56M | 1.26 | 2.82M | +3% | +$4.67M | 0.03 | |
| Acadian Asset Management | $158.44M | 1.24 | 2.78M | -7.77% | -$13.36M | 0.56 | |
| LSV Asset Management | $156.94M | 1.23 | 2.75M | +2.34% | +$3.59M | 0.33 | |
| Jacobs Levy Equity Management | $143.26M | 1.12 | 2.51M | +7.61% | +$10.13M | 0.64 | |
| Armistice Capital Llc | $124.6M | 0.97 | 2.19M | +826.77% | +$111.16M | 1.49 | |
| Bellevue Group | $122.68M | 0.96 | 2.15M | -0.15% | -$189,767.07 | 1.87 | |
| Man Group Plc | $119.56M | 0.94 | 2.1M | -11.69% | -$15.83M | 0.3 | |
| Legal & General | $111.03M | 0.87 | 1.95M | -0.36% | -$401,808.79 | 0.03 | |
| Northern Trust | $105.45M | 0.82 | 1.85M | -6.59% | -$7.44M | 0.02 | |
| Fidelity Investments | $92.51M | 0.72 | 1.62M | +22.09% | +$16.74M | 0.01 | |
| AQR Capital | $88.91M | 0.7 | 1.56M | +31.96% | +$21.53M | 0.15 | |
| Los Angeles Capital Management LLC | $87.76M | 0.69 | 1.54M | -1.9% | -$1.7M | 0.3 | |
| KBC Group | $87.67M | 0.69 | 1.54M | +61.01% | +$33.22M | 0.28 | |
| Candriam S C A | $83.96M | 0.66 | 1.47M | +41.67% | +$24.7M | 0.54 | |
| D. E. Shaw & Co. | $78.94M | 0.62 | 1.39M | -7.69% | -$6.58M | 0.11 | |
| Two Sigma Advisers LP | $76.48M | 0.6 | 1.34M | -24.12% | -$24.31M | 0.13 | |
| Sofinnova | $75.61M | 0.59 | 1.33M | +347.51% | +$58.71M | 0.16 | |
| Charles Schwab | $75.48M | 0.59 | 1.32M | -0.14% | -$105,679.35 | 0.02 | |
| Qube Research & Technologies | $69.65M | 0.55 | 1.22M | +27.6% | +$15.07M | 0.08 | |
| BNY Mellon | $69.06M | 0.54 | 1.21M | -4.25% | -$3.06M | 0.01 | |
| Ubs Asset Management Americas Inc | $68.74M | 0.54 | 1.21M | -0.92% | -$637,095.52 | 0.03 | |
| Connor Clark & Lunn Investment Management Ltd | $67.65M | 0.53 | 1.19M | +29.58% | +$15.44M | 0.16 | |
| HSBC | $66.95M | 0.52 | 1.18M | +15.41% | +$8.94M | 0.05 | |
| APG Asset Management | $61.39M | 0.52 | 1.16M | +8.94% | +$5.04M | 0.11 | |
| Robeco Institutional Asset Management B.V. | $65.61M | 0.51 | 1.15M | +8.06% | +$4.9M | 0.14 | |
| Woodline Partners LP | $64.58M | 0.51 | 1.13M | +0.06% | +$38,454.75 | 0.61 | |
| CalPERS | $63.19M | 0.49 | 1.11M | -5.19% | -$3.46M | 0.04 | |
| Jupiter Fund Management | $61.63M | 0.48 | 1.08M | -1.06% | -$662,845.95 | 0.17 | |
| Two Sigma | $60.07M | 0.47 | 1.05M | -44.84% | -$48.84M | 0.1 | |
| Voloridge Investment Management, LLC | $59.7M | 0.47 | 1.05M | -16.88% | -$12.12M | 0.13 | |
| Deutsche Bank | $59.51M | 0.47 | 1.04M | -5.8% | -$3.66M | 0.03 | |
| Russell Investments Group Ltd | $58.9M | 0.46 | 1.03M | +7.32% | +$4.02M | 0.08 | |
| Dimensional Fund Advisors | $54.16M | 0.42 | 950,604 | <0.01% | -$1,253.34 | 0.02 | |
| Federated Hermes | $53.29M | 0.42 | 935,370 | +4.98% | +$2.53M | 0.12 | |
| First Trust | $50.93M | 0.4 | 894,006 | -2.65% | -$1.39M | 0.05 | |
| Ameriprise Financial | $48.8M | 0.38 | 856,545 | -3.89% | -$1.97M | 0.01 | |
| Millennium Management LLC | $47.57M | 0.37 | 834,969 | -47.71% | -$43.4M | 0.03 | |
| Prudential Financial | $43.89M | 0.34 | 770,414 | +503.48% | +$36.62M | 0.06 | |
| Credit Suisse | $42.28M | 0.33 | 742,187 | +0.08% | +$33,327.45 | 0.04 | |
| Goldman Sachs | $41.29M | 0.32 | 724,845 | -38.5% | -$25.85M | 0.01 | |
| Bank of Montreal | $37.24M | 0.29 | 652,786 | +46.03% | +$11.74M | 0.01 |